冠昊生物(300238.SZ):2021年度淨利預增50%-70%
格隆匯1月13日丨冠昊生物(300238.SZ)公佈2021年年度業績預吿,公司2021年度歸屬於上市公司股東的淨利潤7000萬元-7900萬元,比上年同期增長50%-70%;扣除非經常性損益後的淨利潤4780萬元–5680萬元,比上年同期增長40%-66%。
報吿期內,公司業績與上年同期相比實現同向上升,主要影響因素有以下幾個方面:
1.公司積極貫徹落實國家“十四五”發展規劃,穩字當頭,在保證穩生產、穩經營的大前提下大力推動上市公司高質量發展。報吿期內,公司持續加大市場開拓力度,堅持以市場為導向,積極響應國家政策,調整經營及營銷策略,加強資源配置與協同,同時公司也進一步加大了成本控制的力度。報吿期內,在公司全員共同努力下,公司主要業務板塊銷售收入較上年同期實現快速增長。
2.神外代理產品前期戰略佈局效果明顯,銷售收入較上年同期增長50%。另外,公司隨着市場的變化及時轉變經營思路,優化原有營銷渠道,整合公司營銷資源,推動新渠道建設,優化產品結構,公司整體毛利率較上年同期增加了3%。
3.為保持和擴大公司的技術領先優勢,堅持科技創新,公司繼續加強研發項目的投入,報吿期內,研究費--費用化支出約4600萬元(2020年同期研究費--費用化支出3425.32萬元)。
4.公司預計2021年度非經常性損益對歸屬於上市公司股東的淨利潤的影響金額約2220萬元(2020年同期非經常性損益對淨利潤的影響金額為1238.76萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.